clinical trial · NCT05738538
Expanded Access to Ziftomenib
Acute Lymphoblastic Leukemia, With Appropriate MutationsAcute Myeloid Leukemia, With NPM1 Mutationsziftomenib
brief summary
Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with NPM1 mutations or KMT2A rearrangements. To request access, use Responsible Party contact information provided in this record. Expanded access for ziftomenib is only available in the United States.
started
—
primary completion
—
completion
—
last updated
Jun 4, 2025
detailed description
• Subsection Condition:
* NPM1 mutation in AML patients * KMT2A rearrangement in AML patients * KMT2A rearrangement in ALL patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol